| | | | | | | | | | | | | | | | |
| | |
 | Issue Date FY: 2023 ( Subtotal = $5,071,373 ) |
| | 2023 | 2023 | HMH HOSPITALS CORPORATION | 343 THORNALL ST | EDISON | NJ | 08837-2206 | MIDDLESEX | USA | R00CA245488 | Leveraging behavioral science to improve patient understanding of advanced cancer | 000 | 4 | NIH | 12/1/2022 | $249,000 |
| | 2023 | 2023 | HMH HOSPITALS CORPORATION | 343 THORNALL ST | EDISON | NJ | 08837-2206 | MIDDLESEX | USA | R21AI174118 | Identifying drug-resistant Candida species using SuperSelective primer PCR | 000 | 1 | NIH | 11/25/2022 | $269,850 |
| | 2023 | 2023 | HMH HOSPITALS CORPORATION | 343 THORNALL ST | EDISON | NJ | 08837-2206 | MIDDLESEX | USA | R21AI168729 | Elucidating mediators of genetic instability in Candida glabrata | 000 | 1 | NIH | 11/9/2022 | $277,372 |
| | 2023 | 2023 | HMH HOSPITALS CORPORATION | 343 THORNALL ST | EDISON | NJ | 08837-2206 | MIDDLESEX | USA | 2B2CMS331786 | Integrated Care for Kids (InCK) | 00 | 4 | CMS | 12/15/2022 | $1,991,406 |
| | 2023 | 2023 | HMH HOSPITALS CORPORATION | 343 THORNALL ST | EDISON | NJ | 08837-2206 | MIDDLESEX | USA | R37CA250661 | Harnessing the thymus for long-term tumor control with hematopoietic stem cell-derived naive CAR T cells | 000 | 2 | NIH | 1/30/2023 | $543,694 |
| | 2023 | 2023 | HMH HOSPITALS CORPORATION | 343 THORNALL ST | EDISON | NJ | 08837-2206 | MIDDLESEX | USA | R01AI150765 | Immunometabolic regulations of pulmonary TB pathogenesis by adiposetissue | 000 | 5 | NIH | 12/15/2022 | $764,187 |
| | 2023 | 2022 | HMH HOSPITALS CORPORATION | 343 THORNALL ST | EDISON | NJ | 08837-2206 | MIDDLESEX | USA | CE146126 | Community Project Funding/Congressionally Directed Spending - Construction | 02 | 1 | HRSA | 11/7/2022 | $0 |
| | 2023 | 2022 | HMH HOSPITALS CORPORATION | 343 THORNALL ST | EDISON | NJ | 08837-2206 | MIDDLESEX | USA | H79TI084385 | I.C.A.R.E. - Integrated Care for Addiction Recovery Expansion | 000 | 2 | SAMHSA | 12/1/2022 | $0 |
| | 2023 | 2022 | HMH HOSPITALS CORPORATION | 343 THORNALL ST | EDISON | NJ | 08837-2206 | MIDDLESEX | USA | R01CA254274 | Study of the IL-33-driven immune cell organization underpinning responses to immune checkpoint blockade cancer therapy | 001 | 3 | NIH | 11/23/2022 | $244,207 |
| | 2023 | 2022 | HMH HOSPITALS CORPORATION | 343 THORNALL ST | EDISON | NJ | 08837-2206 | MIDDLESEX | USA | R01AI145436 | Translational approaches to improve understanding and outcome in Tuberculous meningitis | 000 | 3 | NIH | 1/5/2023 | $0 |
| | 2023 | 2022 | HMH HOSPITALS CORPORATION | 343 THORNALL ST | EDISON | NJ | 08837-2206 | MIDDLESEX | USA | T1433114 | ANE - Nurse Practitioner Residency Program | 02 | 4 | HRSA | 1/26/2023 | $0 |
| | 2023 | 2022 | HMH HOSPITALS CORPORATION | 343 THORNALL ST | EDISON | NJ | 08837-2206 | MIDDLESEX | USA | CE147180 | Community Project Funding/Congressionally Directed Spending - Construction | 01 | 1 | HRSA | 11/7/2022 | $0 |
| | 2023 | 2022 | HMH HOSPITALS CORPORATION | 343 THORNALL ST | EDISON | NJ | 08837-2206 | MIDDLESEX | USA | R01CA263662 | Leveraging Social Media to Increase Lung Cancer Screening Awareness, Knowledge and Uptake in High-Risk Populations | 001 | 2 | NIH | 12/16/2022 | $731,657 |
|
| Issue Date FY: 2022 ( Subtotal = $90,014,212 ) (Continued on the next page) |
| | 2022 | 2022 | HMH HOSPITALS CORPORATION | 343 THORNALL ST | EDISON | NJ | 08837-2206 | MIDDLESEX | USA | R01AI139874 | Ezh2 regulates follicular helper T cell differentiation | 000 | 6 | NIH | 8/4/2022 | $468,939 |
| | 2022 | 2022 | HMH HOSPITALS CORPORATION | 343 THORNALL ST | EDISON | NJ | 08837-2206 | MIDDLESEX | USA | R00CA245488 | Leveraging behavioral science to improve patient understanding of advanced cancer | 001 | 3 | NIH | 9/15/2022 | $43,745 |
| | 2022 | 2022 | HMH HOSPITALS CORPORATION | 343 THORNALL ST | EDISON | NJ | 08837-2206 | MIDDLESEX | USA | R00CA245488 | Leveraging behavioral science to improve patient understanding of advanced cancer | 000 | 3 | NIH | 4/18/2022 | $249,000 |
| | 2022 | 2022 | HMH HOSPITALS CORPORATION | 343 THORNALL ST | EDISON | NJ | 08837-2206 | MIDDLESEX | USA | R00AI141622 | Elucidating the roles of systemic and mucosal complement in protection against invasive fungal infections impacting hematopoietic cell transplant | 000 | 2 | NIH | 7/5/2022 | $249,000 |
| | 2022 | 2022 | Hmh Hospitals Corporation | 343 Thornall St | Edison | NJ | 08837-2206 | MIDDLESEX | USA | 2B2CMS331786 | Integrated Care for Kids (InCK) | 00 | 3 | CMS | 12/15/2021 | $1,998,437 |
| | 2022 | 2022 | HMH HOSPITALS CORPORATION | 343 THORNALL ST | EDISON | NJ | 08837-2206 | MIDDLESEX | USA | 2B2CMS331786 | Integrated Care for Kids (InCK) | 02 | 3 | CMS | 9/20/2022 | $0 |
| | 2022 | 2022 | HMH HOSPITALS CORPORATION | 343 THORNALL ST | EDISON | NJ | 08837-2206 | MIDDLESEX | USA | 2B2CMS331786 | Integrated Care for Kids (InCK) | 03 | 3 | CMS | 9/21/2022 | $0 |
| | 2022 | 2022 | HMH HOSPITALS CORPORATION | 343 THORNALL ST | EDISON | NJ | 08837-2206 | MIDDLESEX | USA | R01AI150765 | Immunometabolic regulations of pulmonary TB pathogenesis by adiposetissue | 000 | 4 | NIH | 12/10/2021 | $764,187 |
| | 2022 | 2022 | HMH HOSPITALS CORPORATION | 343 THORNALL ST | EDISON | NJ | 08837-2206 | MIDDLESEX | USA | R00CA229979 | Experimental evolution of pancreatic cancer | 000 | 3 | NIH | 8/22/2022 | $249,000 |
| | 2022 | 2022 | HMH HOSPITALS CORPORATION | 343 THORNALL ST | EDISON | NJ | 08837-2206 | MIDDLESEX | USA | T2246942 | Dental Reimbursement Program | 00 | 1 | HRSA | 8/18/2022 | $133,135 |
| | 2022 | 2022 | HMH HOSPITALS CORPORATION | 343 THORNALL ST | EDISON | NJ | 08837-2206 | MIDDLESEX | USA | R00CA245123 | Elucidating the Role of SMAD4 in Colorectal Cancer | 000 | 3 | NIH | 6/1/2022 | $249,000 |
| | 2022 | 2022 | HMH HOSPITALS CORPORATION | 343 THORNALL ST | EDISON | NJ | 08837-2206 | MIDDLESEX | USA | R37CA250661 | Harnessing the thymus for long-term tumor control with hematopoietic stem cell-derived naive CAR T cells | 000 | 1 | NIH | 2/28/2022 | $592,644 |
| | 2022 | 2022 | HMH HOSPITALS CORPORATION | 343 THORNALL ST | EDISON | NJ | 08837-2206 | MIDDLESEX | USA | H79SM084539 | Hackensack Meridian Carrier Clinic Mental Health Awareness in Identifying Disturbances in Emotions Program (AIDE) | 001 | 2 | SAMHSA | 6/22/2022 | $124,991 |
| | 2022 | 2022 | HMH HOSPITALS CORPORATION | 343 THORNALL ST | EDISON | NJ | 08837-2206 | MIDDLESEX | USA | R01AI141805 | A dual-beta-lactam strategy for treating multidrug resistant M abscessus | 000 | 4 | NIH | 8/11/2022 | $809,943 |
| | 2022 | 2022 | HMH HOSPITALS CORPORATION | 343 THORNALL ST | EDISON | NJ | 08837-2206 | MIDDLESEX | USA | R01AI141183 | Novel bi-specific immunotherapeutic against high-threat Gram-negative pathogens | 000 | 4 | NIH | 1/14/2022 | $1,142,038 |
| | 2022 | 2022 | HMH HOSPITALS CORPORATION | 343 THORNALL ST | EDISON | NJ | 08837-2206 | MIDDLESEX | USA | R01AI138986 | Novel bi-specific immunoprophylactics against multi-drug resistant Gram-negativebacterial infections | 000 | 5 | NIH | 4/12/2022 | $1,076,832 |
| | 2022 | 2022 | HMH HOSPITALS CORPORATION | 343 THORNALL ST | EDISON | NJ | 08837-2206 | MIDDLESEX | USA | R01AI132374 | Combatting natural resistance and persistence in non-TB mycobacterial disease | 000 | 6 | NIH | 1/20/2022 | $906,704 |
| | 2022 | 2022 | HMH HOSPITALS CORPORATION | 343 THORNALL ST | EDISON | NJ | 08837-2206 | MIDDLESEX | USA | R01AI121080 | CTCF in CD8 T cell homeostasis and anti-viral/tumor immunity | 000 | 6 | NIH | 9/21/2022 | $542,314 |
| | 2022 | 2022 | HMH HOSPITALS CORPORATION | 343 THORNALL ST | EDISON | NJ | 08837-2206 | MIDDLESEX | USA | R01AI112579 | Tcf1 programs CD8 T cell responses to enhance viral and cancer immunity | 000 | 7 | NIH | 4/20/2022 | $522,726 |
| | 2022 | 2022 | HMH HOSPITALS CORPORATION | 343 THORNALL ST | EDISON | NJ | 08837-2206 | MIDDLESEX | USA | R01AI106398 | Target based discovery of next generation pyrazinamide | 002 | 9 | NIH | 9/9/2022 | $0 |
| | 2022 | 2022 | HMH HOSPITALS CORPORATION | 343 THORNALL ST | EDISON | NJ | 08837-2206 | MIDDLESEX | USA | R01AI106398 | Target based discovery of next generation pyrazinamide | 001 | 9 | NIH | 5/19/2022 | $791,696 |
| | 2022 | 2022 | HMH HOSPITALS CORPORATION | 343 THORNALL ST | EDISON | NJ | 08837-2206 | MIDDLESEX | USA | R01AI109025 | Critical Factors Influencing Echinocandin Resistance in Candidaglabrata | 000 | 10 | NIH | 7/20/2022 | $710,571 |
| | 2022 | 2022 | HMH HOSPITALS CORPORATION | 343 THORNALL ST | EDISON | NJ | 08837-2206 | MIDDLESEX | USA | R01AI145436 | Translational approaches to improve understanding and outcome in Tuberculous meningitis | 001 | 3 | NIH | 7/14/2022 | $0 |
| | 2022 | 2022 | HMH HOSPITALS CORPORATION | 343 THORNALL ST | EDISON | NJ | 08837-2206 | MIDDLESEX | USA | R01AI161013 | Harnessing B cells for TB vaccine development to improve therapy of TB and TB-HIV coinfection | 000 | 2 | NIH | 7/7/2022 | $1,294,431 |
| | 2022 | 2022 | HMH HOSPITALS CORPORATION | 343 THORNALL ST | EDISON | NJ | 08837-2206 | MIDDLESEX | USA | H79TI084385 | I.C.A.R.E. - Integrated Care for Addiction Recovery Expansion | 002 | 2 | SAMHSA | 7/7/2022 | $522,744 |
| | 2022 | 2022 | HMH HOSPITALS CORPORATION | 343 THORNALL ST | EDISON | NJ | 08837-2206 | MIDDLESEX | USA | R01HL154757 | DOT1L, reconstitution of plasmacytoid dendritic cells and alloimmunity | 004 | 2 | NIH | 8/22/2022 | $68,025 |
| | 2022 | 2022 | HMH HOSPITALS CORPORATION | 343 THORNALL ST | EDISON | NJ | 08837-2206 | MIDDLESEX | USA | R01HL154757 | DOT1L, reconstitution of plasmacytoid dendritic cells and alloimmunity | 001 | 2 | NIH | 3/2/2022 | $612,234 |
| | 2022 | 2022 | HMH HOSPITALS CORPORATION | 343 THORNALL ST | EDISON | NJ | 08837-2206 | MIDDLESEX | USA | R01HL154757 | DOT1L, reconstitution of plasmacytoid dendritic cells and alloimmunity | 003 | 2 | NIH | 4/28/2022 | $425,093 |
| | 2022 | 2022 | HMH HOSPITALS CORPORATION | 343 THORNALL ST | EDISON | NJ | 08837-2206 | MIDDLESEX | USA | U19AI142731 | A CETR-based partnership accelerator for rapid drug development targeting SARS-CoV-2 and pan-CoVs | 001 | 4 | NIH | 4/26/2022 | $6,638,250 |
| | 2022 | 2022 | HMH HOSPITALS CORPORATION | 343 THORNALL ST | EDISON | NJ | 08837-2206 | MIDDLESEX | USA | U19AI171401 | Metropolitan AntiViral Drug Accelerator | 000 | 1 | NIH | 5/16/2022 | $65,141,731 |
| | 2022 | 2022 | HMH HOSPITALS CORPORATION | 343 THORNALL ST | EDISON | NJ | 08837-2206 | MIDDLESEX | USA | R01AG065436 | Rejuvenation of aged hematopoietic stem cells and endothelial niches by thrombospondin-1 blockade | 000 | 4 | NIH | 6/3/2022 | $575,635 |
| | 2022 | 2022 | HMH HOSPITALS CORPORATION | 343 THORNALL ST | EDISON | NJ | 08837-2206 | MIDDLESEX | USA | R01AI145436 | Translational approaches to improve understanding and outcome in Tuberculous meningitis | 000 | 3 | NIH | 3/31/2022 | $693,318 |
| | 2022 | 2022 | HMH HOSPITALS CORPORATION | 343 THORNALL ST | EDISON | NJ | 08837-2206 | MIDDLESEX | USA | CE146126 | Community Project Funding/Congressionally Directed Spending - Construction | 01 | 1 | HRSA | 8/18/2022 | $0 |
| | 2022 | 2022 | HMH HOSPITALS CORPORATION | 343 THORNALL ST | EDISON | NJ | 08837-2206 | MIDDLESEX | USA | CE146126 | Community Project Funding/Congressionally Directed Spending - Construction | 00 | 1 | HRSA | 7/8/2022 | $775,000 |
| | 2022 | 2022 | HMH HOSPITALS CORPORATION | 343 THORNALL ST | EDISON | NJ | 08837-2206 | MIDDLESEX | USA | T1433114 | ANE - Nurse Practitioner Residency Program | 01 | 4 | HRSA | 6/22/2022 | $38,494 |
|
